Q3 FY22 Earnings Presentation

Table of Contents Executive Portfolio Financial Guidance & Summary Highlights Highlights Assumptions ESG Appendix Cardiovascular Growth despite COVID-19 headwinds; share gains continue in CRM Cardiac Rhythm & Heart Failure (CRHF) • Cardiac Rhythm Management ▲ HSD . • Y/Y share gains, with 2x market growth, driven by the strength of our differentiated products, best-in-class patient management systems and global customer engagement o Cardiac Pacing Therapies: HSD growth driven by high-20's Micra TM growth; mid-50s International Micra TM growth including successful launch of Micra™ AV in Japan o Defibrillation Solutions: LSD growth; Cobalt TM & Crome TM share gains; LDD growth in CRT-Ds o Procedure Innovations: Mid-20s growth driven by continued acceleration of TYRX™ global adoption Cardiac Ablation Systems HSD Arctic Front Advance TM cryoablation first line indication for paroxysmal AF gaining traction Agreement to acquire Affera, expanding portfolio into mapping and navigation systems and diagnostic catheters, along with a separate, complementary focal PFA system to our anatomical PFA system Cardiovascular Diagnostics LSD LINQ IITM supply improving; Accu Rhythm TM Al algorithm recently launched in U.S., combining LINQ ||™ leading accuracy with an 84% reduction in false alerts for AF and Pause 12 Q3 FY22 earnings presentation | February 22, 2022 Micra™ AV and VR Transcatheter Pacing System 27% Structural Heart & Aortic Cardiovascular O 22% Coronary & Peripheral Vascular Medtronic $51% Cardiac Rhythm & Heart Failure

View entire presentation